Conduit Pharmaceuticals (FRA:ZK7) Stock Based Compensation : €1.33 Mil (TTM As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals Stock Based Compensation?

Conduit Pharmaceuticals's Stock Based Compensation for the three months ended in Mar. 2025 was €0.22 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 was €1.33 Mil.

Conduit Pharmaceuticals Stock Based Compensation Historical Data

The historical data trend for Conduit Pharmaceuticals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Conduit Pharmaceuticals Stock Based Compensation Chart

Conduit Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Stock Based Compensation

0.18

1.56

Conduit Pharmaceuticals Quarterly Data
	Dec21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Stock Based Compensation	Get a 7-Day Free Trial								0.40	0.45	0.32	0.35	0.22

Conduit Pharmaceuticals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.33 Mil.

Conduit Pharmaceuticals Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK7) » Definitions » Stock Based Compensation

Comparable Companies

Traded in Other Exchanges

CDT:USA

Address

4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines